Cystic Fibrosis Research Study

A research study for adults 18 years of age and older, who have been diagnosed with Cystic Fibrosis is now enrolling. This study is being conducted to evaluate the safety and efficacy an experimental treatment for people with Cystic Fibrosis who also have a bacterial infection in their lungs.

You may qualify if you:

  • Are at least 18 years of age
  • Have been diagnosed with Cystic Fibrosis
  • Are currently being treated with inhaled antibiotics (for at least 3 months)

Continue reading Cystic Fibrosis Research Study

Austin Biotech Savara Nets $20M in Series C for Phase 3 Study

Xconomy Texas Austin — A year after releasing results from a Phase 2 clinical trial, Savara Pharmaceuticals has announced $20 million in Series C funding that it will use to take its inhaled version of an antibiotic to Phase 3.

Continue reading Austin Biotech Savara Nets $20M in Series C for Phase 3 Study

Teva announces FDA approval of generic TOBI in the United States

JERUSALEM–(BUSINESS WIRE)–Oct. 14, 2013– Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announces today that the U.S. Food and Drug Administration has granted approval of the generic equivalent to TOBI® (Tobramycin Inhalation Solution Continue reading Teva announces FDA approval of generic TOBI in the United States